ASCO, CCO issue mCRPC guidelines

The American Society of Clinical Oncology and Cancer Care Ontario published new guidelines to treat metastatic castration-resistant prostate cancer that largely reflect how doctors already manage the disease.

The guidelines, published in the Journal of Clinical Oncology, recommend androgen deprivation therapy regardless of other treatments. Alongside androgen deprivation, ASCO and CCO recommended Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) combined with prednisone, Xtandi enzalutamide from Medivation Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. (Tokyo:4503), and in some cases docetaxel combined with prednisone. The guidelines also recommended Xofigo radium-223 from Bayer AG (Xetra:BAYN) to treat patients with bone metastases. ...